CDK2 and neoplasm: In these tumours, cell cycle progression occurs in the presence of both CDK inhibitors, suggesting that the CDK7i is acting via the same pathway as palbociclib where CDK2/4/6 inhibition are no longer relevant in palbociclib-insensitive cells.